Category Archives: Physiology

Fish oil may be an effective treatment for depression, study shows – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Jun 11 2020

A study published in Molecular Psychiatry shows that patient-derived adult stem cells can be used to model major depressive disorder and test how a patient may respond to medication.

Using stem cells from adults with a clinical diagnosis of depression, the University of Illinois at Chicago researchers who conducted the study also found that fish oil, when tested in the model, created an antidepressant response.

UIC's Mark Rasenick, principal investigator of the study, says that the research provides a number of novel findings that can help scientists better understand how the brain works and why some people respond to drug treatment for depression, while others experience limited benefits from antidepressant medication.

It was also exciting to find scientific evidence that fish oil -- an easy-to-get, natural product -- may be an effective treatment for depression."

Mark Rasenick, UIC distinguished professor of physiology and biophysics and psychiatry at the College of Medicine

Major depressive disorder, or depression, is the most common psychiatric disorder. Around one in six individuals will experience at least one depressive episode in their lifetime. However, antidepressant treatment fails in about one-third of patients.

In the study, the UIC researchers used skin cells from adults with depression that were converted into stem cells at Massachusetts General Hospital and then directed those stem cells to develop into nerve cells. The skin biopsies were taken from two types of patients: people who previously responded to antidepressant treatment and people who have previously been resistant to antidepressants.

When fish oil was tested, the models from treatment-sensitive and treatment-resistant patients both responded.

Rasenick says the response was similar to that seen from prescription antidepressants, but it was produced through a different mechanism.

"We saw that fish oil was acting, in part, on glial cells, not neurons," said Rasenick, who is also a research career scientist at Jesse Brown VA Medical Center and president and chief scientific officer at Pax Neuroscience, a UIC startup company. "For many years, scientists have paid scant attention to glia -- a type of brain cell that surrounds neurons -- but there is increasing evidence that glia may play a role in depression. Our study suggests that glia may also be important for antidepressant action.

"Our study also showed that a stem cell model can be used to study response to treatment and that fish oil as a treatment, or companion to treatment, for depression warrants further investigation," Rasenick said.

Source:

Journal reference:

Yu, J., et al. (2020) N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells. Molecular Psychiatry. doi.org/10.1038/s41380-020-0786-5.

See original here:
Fish oil may be an effective treatment for depression, study shows - News-Medical.Net

Treatment with vitamin A analog improves visual function in diabetic mice – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Jun 11 2020

Diabetic retinopathy is a common complication of diabetes and a leading cause of blindness among the working-age population. A new study in the American Journal of Pathology reports that visual function in diabetic mice was significantly improved after treatment with a single dose of visual chromophore 9-cis-retinal, a vitamin A analog that can form a visual pigment in the retina cells, thereby producing a light sensitive element of the retina.

"In an earlier study we found that diabetes causes vitamin A deficiency in the retina, which results in deterioration of vision, even before any vascular changes can be seen. That finding led to the assumption that early changes in vision in diabetes are probably caused by vitamin A deficiency in the retina," explained lead investigator Gennadiy Moiseyev, PhD, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

In the current study investigators hypothesized that treating diabetic mice with 11-cis-retinal could rescue visual function. They investigated its effect in Akita mice, a genetic model of type 1 diabetes, by measuring electroretinogram (ERG) responses, retinal oxidative stress, and neuronal apoptosis (cell death). ERG was performed on two groups of three-month-old Akita mice and one group of non-diabetic control mice matched for age and genetic background. One group of Akita mice was treated with 9-cis-retinal and the other with a vehicle solution. Average blood glucose concentrations and body weights of the mice were measured monthly during the study. Akita mice showed high glucose concentrations throughout the study. ERG recordings and rhodopsin assay were performed two hours after 9-cis-retinal injection, whereas assessment of cell death by ELISA and TUNEL assay were both performed 24 hours after the injection.

Results showed that the visual function in diabetic mice improved significantly after treatment with the single dose of 9-cis-retinal. In addition, researchers reported that the treatment reduced oxidative stress in the retina, decreased retina cell death and retina degeneration, and improved visual function.

This work supports our novel hypothesis that diabetes-induced disturbance of the vitamin A metabolism in the eye is responsible for reduced visual function in early stages of diabetic retinopathy. Currently, there is no available therapy to prevent the development of the retinal complication in patients suffering from diabetes. This study suggests that the delivery of visual chromophore to the diabetic eye may represent a potential therapeutic strategy for the early stages of diabetic retinopathy to prevent vision loss in patients with diabetes."

Gennadiy Moiseyev, Ph.D., Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Traditionally, diabetic retinopathy was considered a disease caused by the pathology of blood vessels in the retina, whereby light-sensitive tissue at the back of the eye (fundus) becomes damaged. Patients with diabetes often experience functional deficits in dark adaptation, contrast sensitivity, and color perception before any microvascular pathologies are detected on the eye fundus. However, recent data underscore the importance of vitamin A for normal visual function. It serves as a precursor for light-sensitive 11-cis-retinal, the chromophore of visual pigments that can produce a light-sensitive protein in the retina.

Source:

Journal reference:

Malechka, V.V., et al. (2020) The Single Administration of a Chromophore Alleviates Neural Defects in Diabetic Retinopathy. American Journal of Pathology. doi.org/10.1016/j.ajpath.2020.03.009.

Originally posted here:
Treatment with vitamin A analog improves visual function in diabetic mice - News-Medical.Net

Interferons being tested for COVID-19 may increase susceptibility to bacterial infections – News-Medical.Net

Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.

The results suggest that the timing and duration of this treatment may need to be carefully selected, as trials move forward, to avoid deleterious effects.

Interferons (IFNs) help fight viral infections in the lung. In particular, type III IFNs (IFN- ) have attracted much attention, because, unlike other IFNs, they show antiviral effects without driving inflammatory responses.

Already, a clinical trial exploring the use of IFN- against SARS-CoV-2 has begun. Despite interest in the use of IFN- to treat viral infections, the long-term effects IFN- on lung physiology - and in possibly impairing bacterial control by the lung epithelium - remain largely overlooked.

Here, to directly evaluate whether SARS-CoV-2 induces IFNs, Achille Broggi and colleagues tested swabs of COVID-19 patients and healthy controls, as well as the bronchoalveolar lavage fluid of severe SARS-CoV-2-positive patients.

In the latter group, levels of type I and III interferons were high, the report. Next, to better understand the effects of IFN- signaling in the lung, Broggi, and colleagues studied the lungs of mice exposed to synthetic viral RNA.

In these animals, IFN- secreted by dendritic cells caused damage to the lung epithelium, which increases susceptibility to lethal bacterial superinfections. In a separate study using a mouse model to investigate the dynamics of influenza virus infection, Jack Major et al. report that IFN signaling (especially that of IFN-) hampered lung repair.

This pair of papers suggests that the timing and duration of IFN- exposure are critical parameters underlying the success or failure of antiviral therapeutics, the authors say.

[O]ur data enjoin clinicians to carefully analyze the duration of IFN- administration and to take into consideration the severity of the disease when IFN- is used as a therapeutic agent against lung viral infections,"

Broggi and Colleagues, American Association for the Advancement of Science

"Optimal protection would be achieved by strong induction of IFN-stimulated genes early during infection to curb viral replication, followed by timely down-regulation of IFN responses, enabling efficient lung epithelial repair," says Major et al.

Source:

Journal reference:

Broggi, A., et al. (2020) Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. doi.org/10.1126/science.abc3545.

Read this article:
Interferons being tested for COVID-19 may increase susceptibility to bacterial infections - News-Medical.Net

‘Tsunami’ of distress could hit with healthcare workers at particular risk – Cork Beo

Ireland's government needs to prioritise mental health as a "tsunami of psychological distress" could be on the way.

That is the warning coming from the Irish Medical Journal after a leading doctor took a look at the potential impact of the pandemic's aftermath.

Dr Joe Jordan from The Royal College of Surgeons Ireland looked at the similar SARS and MERS epidemics and wrote that the country needs to learn from them and pump funding into services so they're ready for what could come next.

Although it's not clear what the Covid-19 aftermath will look like, he says looking at SARS and MERS might give some clues.

In one study of SARS survivors, 44 percent developed PTSD at some stage over four years of monitoring.

He said that the effect of the epidemic in Hong King saw "reduced subjective levels of wellbeing" amongst people with characteristics including "unemployment, low education, and chronic illness".

We're testing a new site:This content is coming soon

There was also a reported psychological impact on people due to quarantine and that it can be "wide-ranging, substantial, long-lasting, and lead to high levels of stress and psychological distress".

Dr Jordan warned that healthcare workers who were involved in the care of SARS patients suffered higher levels of burnout, physiological distress, and PTSD compared to those who weren't involved.

Similarly, MERS patients saw anxiety symptoms and "anger" for four to six months after being released from isolation.

Although they say the long-term impact of coronavirus is unknown, "particular attention" needs to be given to healthcare workers over the coming years.

He wrote that "robust community and hospital based mental health services" will need to be available along with online physiology services.

"Timely and adequate access will need to be a priority for healthcare systems both during and after the pandemic

"Robust community and hospital based mental health services, in addition to online psychological supports will be required.

"We propose healthcare workers, the elderly, patients with active or psychiatric histories and the homeless sector to be at particular risk of psychological distress and targeted interventions in these groups will be needed.

"We believe exercise therapies will play a key role in the rehabilitation of Covid-19 survivors."

Originally posted here:
'Tsunami' of distress could hit with healthcare workers at particular risk - Cork Beo

Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies – BioSpace

GOTHENBURG, Sweden, June 11, 2020 /PRNewswire/ -- Using the AbiprotTMantibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients. The epitope is part of the spike protein which mediates the virus entry into cells. It was identified in a pilot study using virus material from the nasal swab of a Covid-19 patient.

This early proof-of-concept result is very encouraging and has prompted Oblique Therapeutics and their collaborators to continue the work to map additional epitopes on the SARS-CoV-2 virion surface. The company will make all results freely available for vaccine and antibody-developing Pharma and Biotech companies.

Dr. Sreesha P Srinivasa, Ph.D., Senior Vice President, Translational R&D, Oblique Therapeutics, commented "As an innovation-driven biotechnology company and a responsible member of the scientific community, Oblique Therapeutic is committed to contribute towards a long lasting solution to the Covid-19 pandemic. In this effort, we decided to employ our unique AbiprotTMplatform to interrogate the surface of SARS-CoV-2 virion for identification of novel epitopes that could potentially be accessible to antibodies. We are very encouraged by the results from a pilot experiment with limited virus material that has led to the identification of a potential epitope in the spike protein. We are motivated to continue this effort and identify more epitopes on the surface of the virion. We will make results from this collaborative project freely available to the scientific community upon request"

Collaboration

The research was conducted by Oblique Therapeutics AB in collaboration with scientists from the Department of Clinical Microbiology at Sahlgrenska University Hospital and The Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden and the Department of Physiology and Pharmacology at Karolinska Institutet, Solna, Sweden with support from Nanoxis Consulting AB, Gothenburg, Sweden.

About Abiprot TM

Oblique Therapeutics has developed a unique, proprietary methodology to identify epitopes on protein targets that have previously proven difficult to address with antibodies. AbiprotTM can identify high-affinity antibody binding sites in any given protein with single amino acid resolution. It is based on using a tailored molecular reporter system and proteomics. The platform yields detailed sequence and structure information for epitope identification and development. Oblique is applying this technology for discovery of selective antibody therapeutics targeting, for example, KRAS for the treatment of cancers and several ion channel targets to treat pain.

About Oblique Therapeutics

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises three in-house programs - two antibody candidates: aKRAS in advanced cancer, aTRPA1 in pain; and the small molecule OT-1096 in triple-negative breast cancer. In addition, there are three antibodies programs in collaboration with pharma. Oblique Therapeutics makes medicines that matter to patients.https://obliquet.com/

For more information, please contact:Dr. Sreesha P SrinivasaPh.D.Senior Vice PresidentTranslational R&D Oblique TherapeuticsEmail: Sreesh@obliquet.com

For more information in the Scandinavian countries, please contact:Prof. Owe OrwarCEOOblique TherapeuticsEmail: owe@obliquet.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oblique-therapeutics-ab/r/press-release-june-11--2020,c3132564

View original content:http://www.prnewswire.com/news-releases/oblique-therapeutics-ab-has-identified-a-potentially-important-epitope-for-generation-of-sars-cov-2-antibodies-301074513.html

SOURCE Oblique Therapeutics AB

Read the rest here:
Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies - BioSpace

Scientists and economists from Honoris United Universities in global selection for Lindau Nobel Laureate Meetings – How we made it in Africa

MoU signing with the Council and Foundation for the Lindau Nobel Laureate Meetings and Honoris United Universities in 2019.

Press Office:Honoris United Universities

The selection of eight young scientists and economists from the network represents the strengthening of ties between Honoris and Lindau Nobel Laureate Meetings in promoting research in Africa

Honoris United Universities, the first and largest pan-African network of private higher education institutions, today announced that five science and three economics students from across the network have been selected amongst 1,034 young scientists and economists from over 100 countries to participate in the 70th Lindau Nobel Laureate Meeting and the 7th Lindau Meeting on Economic Sciences in 2021.

The Meetings, which will bring together young scientists and economists alongside Nobel Laureates in physics, chemistry, physiology and medicine, as well as economic sciences from across the world, form part of a partnership established between Honoris United Universities and Lindau Nobel Laureate Meetings last year, to increase participation and research in the natural sciences and in economics across Africa.

The selected Honoris scientists and economists successfully completed a multi-stage selection process, which involved 144 academic partners of the Lindau Nobel Laureate Meetings and German universities in the field of economics including the Wirtschafts und Sozialwissenschaftliche Fakulttentag (WISOFT Association of Economics and Social Sciences Faculties). The successful students were selected from leading African universities within the Honoris network including Universit Mundiapolis in Morocco, Universit Centrale in Tunisia, and REGENT Business School in South Africa.

CEO of Honoris United Universities, Luis Lopez said, As an Academic Partner to the Lindau Nobel Laureate Meetings, we are extremely proud to support and promote the development of world-class African talent as evidenced by our exemplary students, selected to participate in this extremely competitive and prestigious event. They are a testament to the learning being undertaken in our institutions and to the faculty members focused on student success and institutional research. This is a superb opportunity for our students to represent research in economics and in natural sciences from Africa as part of a landmark global event.

Due to the Covid-19 pandemic, the onsite interdisciplinary 70th Lindau Nobel Laureate Meeting and the Lindau Meeting on Economic Sciences, originally planned for 2020, are postponed to 2021. The 70th Lindau Nobel Laureate Meeting will now take place from 27 June 2 July 2021 and 7th Lindau Meeting on Economic Sciences will take place from 24 28 August 2021.

For 2020, the Lindau Nobel Laureate Meetings will be introducing two exciting online forums, bringing together some 40 Nobel Laureates, Lindau Alumni and the selected young scientists and economists from across the world to exchange knowledge, ideas and questions via a series of interactive and high level activities.

This will include the Online Sciathon 2020 2020 (19 21 June), a 48-hour hackathon-style event involving Lindau Alumni and the young scientists and economists on topics relating to global, sustainable and cooperative open science, climate change and capitalism after Covid-19.

The Sciathon will be followed by the Online Science Days 2020 (28 June 1 July) for Nobel Laureates, Lindau Alumni and the young scientists and economists invited for 2021. They will participate in debates, conversations, talks and next gen science sessions with each comprising live Q&A sessions. Invited guests as well as media representatives will be able to follow the whole programme online and interested parties may register for access, including future young scientists or economists, prospective academic partners or benefactors.

Since its foundation in 1951, around 400 Nobel Laureates have attended the Lindau Nobel Laureate Meetings, held each year as a forum for scientists of different generations, cultures and disciplines to convene and exchange knowledge, ideas and experiences. The theme is alternated each year and is based on the three natural science Nobel Prize disciplines physics, chemistry and physiology and medicine. An interdisciplinary meeting based around all three natural sciences is held every five years and a Lindau Meeting on economic sciences is held every three years.

The Lindau Nobel Laureate Meetings foster the exchange among scientists of different generations, cultures, and disciplines. Once every year, around 30-40 Nobel Laureates convene in Lindau to meet the next generation of leading scientists: 600 undergraduates, PhD students, and post-doc researchers from all over the world. The Lindau Meetings cooperate with more than 200 of the most renowned science and research institutions worldwide to identify the most qualified participants. The scientific programme of each Lindau Meeting is based on the principle of dialogue. The different sessions lectures, Agora Talks, masterclasses, and panel discussions are designed to activate the exchange of knowledge, ideas, and experience between and among Nobel Laureates and young scientists.

http://www.honoris.net

Follow this link:
Scientists and economists from Honoris United Universities in global selection for Lindau Nobel Laureate Meetings - How we made it in Africa

Yoga and the pineal gland: Sadhguru on why yogic sadhana aims first for stability, not ecstasy – Times Now

Yoga and the pineal gland: Sadhguru on why yogic sadhana aims first for stability, not ecstasy  |  Photo Credit: iStock Images

As scientists find better instruments to study the human brain, one thing is becoming clear: there is much more to be known about the mind than we right now know. One aspect of yogic physiology that aligns with modern neurosciences has to do with the pineal gland. This gland was always recognised as being associated with the agna chakra. Today, neuroscientists say that the secretions of the pineal gland control one's moods and experiences.

While medical sciences have made it clear that chemicals can create pleasant and unpleasant experiences within you that are very real for you. Actually, you are causing everything to yourself. The only difference is whether you cause it with or without outside help. If you simply become ecstatic right now, you are creating it without outside help. If you cause the same thing with outside stimulation, it may be the same thing experience-wise, but the end result could damage the system. Unconscious experiences, however big they are, are of no significance for one's growth and transformation.

An aspect of yogic physiology which is totally absent in modern medical sciences is something which I constantly keep on within myself, called the bindu. Bindu means a tiny point. It is a particular spot on the pineal gland. If you touch the bindu, it will release secretions that make you feel ecstatic. But the bindu has another point to it which also has a secretion but is poisonous. If you tip the wrong side of the glass, then poison will spread through the system. It will spread through the system in such a way that, for what looks like simply no reason, you are miserable. A lot of people have done that to themselves. They have become miserable by doing improper things with life.

In yoga, the initial phases of sadhana are aimed at stability, not ecstasy. If ecstasy comes before stability, you are heading for a crash. If ecstasy comes after stability, it is fantastic. The processes of ecstasy were never written down. It is only in the presence of a certain being that those things happen because they are very subjective. In some books on tantra, they have tried to write it down, which I feel is very irresponsible. Suppose you read a book where the first two chapters talk about some simple practices to stabilize yourself and the last five chapters talk about practices to take you to ecstatic levels which one will you do? People will not go for stability, they will go for ecstasy and they will break up.

Never aspire for anything that is not yet in your perception. Just do your sadhana. That is why traditions have always been insisting on trust. If you did not know how a plant grows, if I show you a lump of filth and the beautiful flower and say, These two things are the same... would you believe me? It takes a crazy sense of trust. That is why we do not talk about all those things. Because this cannot be logically worked out. That is why the Guru came into the picture, because a little fixing is needed. Without a little fixing, you will not cross the line.

Sadhguru is a guest contributor. Views expressed are personal.

Read the original post:
Yoga and the pineal gland: Sadhguru on why yogic sadhana aims first for stability, not ecstasy - Times Now

Health Care Hero: Imaging workers also on the front lines – Dayton Daily News

The Dayton Daily News is profiling the people who work hard every day to save lives and take care of us. Nominate a Health Care Hero by emailing Rebecca.Mullins@coxinc.com.

Name: Brianne Grizzle

Hometown: I was born and raised in Middletown and now reside in Franklin.

Job Title: CT Technologist

Where do you work: I work at Atrium Medical Center in the Medical Imaging Department

COMPLETE CORONAVIRUS COVERAGE

Describe what your day is like/what you do: As a CT technologist, I am responsible for multiple things. I run the computed tomography scanners that take the X-rays of the patients. I also collect histories from the patients that is pertinent for the exams to relay for the radiologists reading their images. I start IVs, help transfer and position them on the tables for exams in specific ways that can eliminate the dosage of radiation they will receive. Throughout all of these responsibilities, I am doing my best patient care and aiming to take the best pictures in order to help diagnose internal and external injuries, as well as cancers and diseases. I see my purpose as to try to give the most compassion and care for the patients in their most stressful and life threatening times.

What inspired you to get into health care? What inspired me to get into health care was honestly kind of random for me. I had changed majors in college two times previously before choosing radiology. I always knew I had an interest in anatomy and physiology from taking science classes throughout my schooling, but never paid attention to my own thoughts! Now I am so happy I chose a field with many opportunities for growth. I have started as a general X-ray technologist, progressed to a CT technologist, as well as having experience as an MRI technologist.

Health Care Hero: I really love my job

Whats a memorable experience youve had in health care? A memorable experience for me would be really hard to pinpoint because there has been so many with patients and their families. Patients are so grateful to just receive the slightest amount of kindness and caring from medical professionals. By giving someone a warm blanket at the end of my test makes all the difference in trying to make their hospital stay as comfortable as possible.

Health Care Hero: I became a nurse to make a difference

What do you want readers to know about your job right now? What I want readers to know is that all of medical imaging is also in the front line. Great respect definitely go out to the nurses who care for critically ill patients around the clock, but we are often overlooked. Although some of our tests are not long with the patients, we still make an impact on our interactions with them. Our short contacts with patients can become extremely emotional and personal. They are only sent to us because they have a problem such as an broken bone, internal problems, or a mass that they are trying to see if it is cancerous or not. I am the first one to see those images and even if I am able to see a negative outcome for the patient, I have to continue to smile and stay positive until the doctors can relay the results of the tests to them. That is probably the hardest part is continuing to smile for the patients despite their worst nightmares potentially coming true.

Thank you for reading the Dayton Daily News and for supporting local journalism. Subscribers: log in for access to your daily ePaper and premium newsletters.

Thank you for supporting in-depth local journalism with your subscription to the Dayton Daily News. Get more news when you want it with email newsletters just for subscribers. Sign up here.

See more here:
Health Care Hero: Imaging workers also on the front lines - Dayton Daily News

Science Interactive Group Partners with BioDigital to Offer Virtual Dissections for Distance-Learning STEM Students in Higher Ed – Business Wire

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Science Interactive Group (SIG) and BioDigital, Inc., two companies at the forefront of the education technology industry, have partnered to provide students and educators with more flexibility in the distance learning space. SIG will embed the BioDigital Human Platform into its lab experiments, allowing online lab science students the option to perform virtual dissections that are supported by custom curriculum.

Partnering with BioDigital enables SIG to offer the option of virtual dissections to our customer base. We believe strongly in offering instructors the benefit of choice when selecting the labs that support their curriculum, said Tim Loomer, CEO of SIG.

The industry leader in distance learning content, lab materials, and education software for higher education institutions, SIG oversees two major providers of online lab science experiments and curricula, Hands-On Labs and eScience Labs. By combining customizable physical lab kits with digital learning tools and a cloud-based educational platform, SIG replicates the tactile lab experience for distance learners, expanding access to STEM education.

BioDigital, whose flagship app has more than four million registered users, provides the world's first 3D human visualization platform. Likened to Google Earth for the human body, the BioDigital Human Platform is an interactive software featuring more than 8,000 individually selectable anatomical structures. Each system is fully segmented, labeled and dissectible for easy configuration to meet any educational need, and the platform uses innovative, cloud-based technology to enable users to view human anatomy and disease in an intuitive visual format. Featuring the most complete, scientifically accurate 3D body ever assembled, BioDigital is utilized by top medical schools and students from over 3000 schools.

By collaborating with BioDigital, SIG is further diversifying its selection of digital learning tools to meet the needs of its expanding market. The ability to choose between physical and virtual dissections in an online course empowers Anatomy and Physiology educators to tailor the distance-learning experience in new ways without sacrificing learning objectives.

BioDigital CEO Frank Sculli noted, With the acceleration to at-home learning, partnering with a forward-thinking organization such as Science Interactive Group that can rapidly integrate our virtual body software to provide thousands of students a richer, more engaging learning experience is an exciting step towards fulfilling our mission of making health and human body more understandable to all people.

About Science Interactive Group

Science Interactive Group encompasses multiple brands, including Hands-On Labs, eScience Labs, StarLab, Science First, BioDigital and Wildco that provide science education solutions to higher education institutions, K-12 institutions, museums, libraries, laboratories, and distributors worldwide. Science Interactive Groups vast assortment of innovative, science-oriented products is designed to provide instructors with interactive, real-world applications that engage students and enhance outcomes. Learn more at ScienceInteractive.com

See the original post here:
Science Interactive Group Partners with BioDigital to Offer Virtual Dissections for Distance-Learning STEM Students in Higher Ed - Business Wire

Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes – The Cardiology Advisor

A set of guidelines regarding the use of multimodality cardiovascular (CV) imaging in young adult competitive athletes, focusing on the distinction between exercise-induced cardiac remodeling (EICR) and cardiac pathology, was formulated by an expert writing group and published in the Journal of the American Society of Echocardiography.

Thisreport was endorsed by the American Society of Echocardiography, in conjunctionwith the Society of CV Computed Tomography (CT) and the Society for CV MagneticResonance (CMR).

Young competitive athletes with unrecognized CV disease (CVD) who undergo strenuous exercise may be at increased risk for serious adverse events, including sudden cardiac death. Expertise in and appropriate utilization of multimodality CV imaging techniques including transthoracic echocardiography (TTE), CT angiography (CTA) and CMR are essential in order to ensure proper diagnosis, risk stratification and ruling out of CVD in this population, as well as for the clinical management of detected pathologies. This requires selection of the appropriate imaging modality, high-quality performance of the imaging technique, as well as accurate interpretation, which demands an in-depth comprehension of EICR which may be modified in young athletes by physiological adaption, and should not be misinterpreted (ie, as resulting from pathophysiology). Cardiac specialists with training in these areas are in an ideal position to provide competitive athletes with comprehensive care.

In most cases in which CVD is suspected or confirmed, initial imaging studies should involve TTE 2-dimensional or Doppler with CTA or CMR follow-up as needed. The advantages of TTE include low cost and high availability, and the fact that this technique can readily be used to characterize myocardial structure, valve and proximal coronary anatomy and physiology, as well as systolic and diastolic function. The use of CMR is especially helpful when investigating potential myocardial pathology, particularly right ventricular (RV) and aortic morphology and function, but its use is limited by high cost and limited accessibility, as well as contraindications in individuals with metal implants. In certain clinical situations, CTA may be ideal, such as when the anatomy of the great vessels or the proximal coronary structures must be precisely defined. However, exposure to ionizing radiation remains a concern.

The imaging specialists who conduct and/or interpret the results of competitive athletes should understand the fundamentals of exercise physiology and EICR. Regarding left ventricular (LV) adaptations in this population, a multifactorial and complex influence of sex, ethnicity, duration of prior exercise, and type of sport determines both the geometry (eccentric vs concentric) and magnitude (chamber volumes/dimensions and absolute wall thickness) of EICR changes. When RV dilation, which is common in endurance athletes, occurs secondary to EICR, there should be concomitant biatrial dilation and eccentric LV hypertrophy/remodeling. It is not uncommon for athletes to have mild aortic dilation. In cases in which absolute aorta measurements exceed 34 mm and 40 mm in women and men, respectively, an initial TTE should be followed by CMR or gated CTA.

The distinction between EICR and pathology demands careful measurement of parasternal long-axis view of LV wall thickness to avoid inclusion of RV chordal tissue and septal trabeculations. There is generally mild LV wall thickening with EICR that varies slightly based on race, and measurements above cutoffs may indicate pathology. Pathologic LV remodeling should be suspected in any patient with LV wall thickening accompanied by indicators of reduced diastolic function and/or longitudinal systolic strain. Incomplete TTE LV visualization or uncertain etiology of thickening should be followed up with CMR.

When LV dilation is suspected on TTE, confirmatory CMR should be performed to better characterize chamber structure and function, with distinction between EICR and pathology requiring integration of the patients history and additional testing results rather than simple assessment of LV or left atrial dilation magnitude. Mild reductions in LV ejection fraction (by 45-55%) that occur alongside RV and biatrial dilation without diastolic dysfunction should be considered as a result of physiologic adaptation.

When RVdilation is detected on TTE without clear etiology, CMR should be performed.Endurance athletes often have RV dilation that is accompanied by LV dilation,and in the absence of structural or functional abnormalities, this adaptationshould be considered physiologic. However, isolated clinical cutoffs normallyused to indicate RV dilation cannot differentiate EICR from pathology in competitiveathletes.

Although physiologic hypertrabeculation of the LV apex is common among competitive athletes, particularly in black and/or endurance competitors, this feature needs tobe distinguished from noncompaction cardiomyopathy. When hypertrabeculation is seen in the context of abnormal LV wall thickness or systolic/diastolic dysfunction and cardiomyopathy is suspected, incomplete TTE visualization of the area should be followed by CMR imaging.

Young adult competitive athletes should undergo a CV screening prior to engaging in sports. This screening should include a focused history and physical exam and may incorporate a 12-lead electrocardiogram. Although TTE, CTA and CMR are not recommended as part of this initial screening, those responsible for such programs must be closely connected to medical centers staffed with sports cardiologists and imaging experts, in order to further evaluate any abnormal findings detected during the process.

Inathletes who present with chest pain, TTE should be used as a first-linestrategy for investigation, followed by maximal effort-limited (not heart rate[HR]-limited)exercise testing with immediate post-exercise TTE before HR recovery can occur.Anomalous coronary vasculature should be excluded through careful examinationof the origins and proximal course of the left and right coronary circulation. Ifthis cannot be accomplished using TTE, CTA or CMR should be performed toclarify coronary anatomy.

Neurally mediated syncope that occurs following exercise or that is unrelated to strenuous effort is common among competitive athletes and does not require evaluation with noninvasive imaging studies. However, when the etiology of syncope is uncertain, and especially when it occurs during exercise, comprehensive assessment is necessary. This evaluation should involve TTE, followed by CTA or CMR, in order to rule out structural or valvular disease. In addition, maximal effort-limited exercise testing should be performed.

Athleteswho report palpitations that begin or intensify during strenuous activityshould undergo TTE initially to look for structural disease. This should befollowed in some cases (based on presentation and TTE findings), by CMR.Maximal effort-limited exercise testing with or without imaging should also beperformed in these patients. In individuals evaluated for symptomatic orasymptomatic ventricular pre-excitation, TTE can exclude complex congenitalheart disease, PRKAG2 gene-mediated hypertrophic cardiomyopathy, and Ebsteinsanomaly.

When a young athlete presents with inappropriate exertional dyspnea, either as a new sign or an indicator of nonresponsiveness to therapy for a previously identified noncardiac cause, a TTE should be performed. This should be followed by maximal effort-limited exercise testing with or without imaging.

Finally,when an athlete reports a decline in performance and his or her initialevaluation suggests possible coronary, myocardial or valvular pathology (orwhen there is no clear explanation for this change), TTE should be performed. Clinicalsuspicions should help determine the addition of CTA, CMR and/or exercisetesting.

Additional recommendations briefly addressed the evaluation of slightly older competitive athletes, pediatric athletes, and those with congenital heart disease.

Differentiating EICRfrom mild forms of pathology remains challenging in clinical practice and corollary data in specific groups, including children and people with congenital heart disease, are sparse. Further acquisition of normative data, particularly data derived from CMR and CTA, may further address these important contemporary clinical challenges, noted the authors.

Conflictsof Interest Disclosures

The following authors reported relationships with one or more commercial interests: Pamela S Douglas, MD, FASE owns stock in UpToDate/Kluwer and is DSMB for REAL TIMI 63B; Christopher M Kramer, MD received grant support from Regeneron and is a consultant for Cytokinetics; Eric Williamson, MD is an unpaid consultant for Siemens Medical and is the recipient of an investigator-initiated research grant from GE Healthcare.

Reference

Baggish AL, Battle RW, Beaver TA, et al. Recommendations on the use of multimodality cardiovascular imaging in young adult competitive athletes: a report from the American Society of Echocardiography in collaboration with the Society of Cardiovascular Computed Tomography and the Society for Card. J Am Soc Echocardiogr. 2020;33(5):523-549. doi:10.1016/j.echo.2020.02.009

See the original post:
Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor